Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 3:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 442 matching trials from the live ClinicalTrials.gov search.
Conditions
Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 90 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Amyotrophic Lateral Sclerosis
Interventions
TCH346
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
21 Years to 80 Years
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Resistance Exercise, Endurance Exercise, Stretching/Range-of-Motion
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Charlestown, Massachusetts + 1 more
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
Acamprosate calcium
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
XT-150
Biological
Lead sponsor
Xalud Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
4
States / cities
Phoenix, Arizona • Baltimore, Maryland • Boston, Massachusetts + 1 more
Conditions
Neurologic Disorder, Paralysis, Paralysis; Stroke, Amyotrophic Lateral Sclerosis, Muscular Dystrophies, Spinal Cord Injuries, Stroke, Lacunar, Stroke Brainstem, Cervical Spinal Cord Injury, Spinal Muscular Atrophy, Tetraplegic; Paralysis, Quadriplegia/Tetraplegia
Interventions
Motor Neuroprosthesis (MNP)
Device
Lead sponsor
Synchron Medical, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Buffalo, New York • New York, New York • Pittsburgh, Pennsylvania
Conditions
Amyotrophic Lateral Sclerosis
Interventions
nL-CHCHD-001
Drug
Lead sponsor
n-Lorem Foundation
Other
Eligibility
48 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Not listed
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Phoenix, Arizona • Atlanta, Georgia
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen D Pridopidine

NCT04615923
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Pridopidine, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
tirasemtiv
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
41
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 36 more
Completed No phase listed Observational Accepts healthy volunteers

Neuromuscular Ultrasound in ALS

NCT01785550
Conditions
ALS
Interventions
Ultrasound of nerve and muscle
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Robotic Glove Use
Device
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Davie, Florida
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Terminated No phase listed Observational Accepts healthy volunteers

Longitudinal Study of Innate Lymphoid Cells in Peripheral Blood in ALS

NCT03090932
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Blood draw
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
ALS, Amyotrophic Lateral Sclerosis
Interventions
Autologous Adipose-derived Mesenchymal Stromal Cells
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Completed Phase 2 Interventional Results available

Mexiletine in Sporadic Amyotrophic Lateral Sclerosis

NCT02781454
Conditions
Sporadic Amyotrophic Lateral Sclerosis
Interventions
Mexiletine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Orange, California • Augusta, Georgia + 7 more
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tampa, Florida
Recruiting No phase listed Observational Accepts healthy volunteers

Biofluid Research on Age-Related or Inherited Neurodegeneration

NCT07798700
Conditions
Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis), Primary Progressive Aphasia (PPA), Familial Frontotemporal Lobar Degeneration (fFTLD), Fronto-temporal Lobar Dementia, Dementia With Lewy Bodies (DLB), Cortical Basal Syndrome (CBS), Alzheimer's Disease (AD), Progressive Supranuclear Palsy(PSP), Parkinson's Disease (PD), Parkinson's Disease Dementia (PDD), Limbic-predominant Age-related TDP-43 Encephalopathy (LATE), Posterior Cortical Atrophy (PCA), Primary Lateral Sclerosis (PLS), Primary Muscular Atrophy (PMA)
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2070
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Amyotrophic Lateral Sclerosis
Interventions
creatine, tamoxifen
Drug
Lead sponsor
Nazem Atassi
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Kansas City, Kansas • Boston, Massachusetts • Worcester, Massachusetts + 6 more
Conditions
Amyotrophic Lateral Sclerosis, Brain Stem Stroke, Cerebral Palsy, Traumatic Brain Injury, Speech Disorders
Interventions
Speech generating device (SGD) evaluation including BCI access, Training and treatment
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
14 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Carnegie, Pennsylvania • Pittsburgh, Pennsylvania
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Abatacept Injection [Orencia] and Proleukin (aldesleukin)
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metastatic Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Parkinson Disease, Interstitial Lung Disease, Amyotrophic Lateral Sclerosis, End Stage Liver Disease, End Stage Renal Disease, Diabetes Complications
Interventions
Respecting Choices First Steps, Five Wishes Form
Behavioral
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Atlanta, Georgia • Columbia, South Carolina + 1 more